Therapeutic Asset Ratings
228 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
ic9-car19 t cells
Lymphoma
UNC Lineberger Comprehensive Cancer Center
P1
C
(37)
Icovamenib
Lymphoma
Biomea Fusion Inc.
P1
C
(37)
JS014
Lymphoma
Anwita Biosciences
P1
C
(37)
Kappa Cd28 T Cells
Lymphoma
Baylor College of Medicine
P1
C
(37)
lb1410
Lymphoma
L & L Bio Co., Ltd., Ningbo, China
P1
C
(37)
LYSINE
Lymphoma
ITM Solucin GmbH
P1
C
(37)
N-Acetyl-L-Cysteine
Lymphoma
Memorial Sloan Kettering Cancer Center
P1
C
(37)
Scri-Hucar19V2
Lymphoma
Seattle Children's Hospital
P1
C
(37)
sg2501
Lymphoma
Hangzhou Sumgen Biotech Co., Ltd.
P1
C
(37)
t-1301 capsules
Lymphoma
Taivex Therapeutics Corporation
P1
C
(37)
Tgfbeta Resistant Lmp-Specific Ctls
Lymphoma
Baylor College of Medicine
P1
C
(37)
Tln-121
Lymphoma
Treeline Biosciences, Inc.
P1
C
(37)
Tln-254
Lymphoma
Treeline Biosciences, Inc.
P1
C
(37)
tp53-epha-2-car-dc
Lymphoma
Chinese PLA General Hospital
P1
C
(37)
vp301
Lymphoma
Virtuoso BINco, Inc.
P1
C
(37)
Zirconium Zr 89 Crefmirlimab Berdoxam
Lymphoma
City of Hope Medical Center
P1
C
(37)
Maplirpacept
Lymphoma
Pfizer
P1
C
(36)
Bisoprolol Fumarate
Lymphoma
University of Arizona
Early P1
C
(34)
Brexucabtagene Autoleucel
Lymphoma
M.D. Anderson Cancer Center
Early P1
C
(34)
Hyaluronidase fihj
Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Early P1
C
(34)
Isoproterenol
Lymphoma
University of Arizona
Early P1
C
(34)
MAGNESIUM METALLICUM
Lymphoma
Mayo Clinic
Early P1
C
(34)
NADOLOL
Lymphoma
University of Arizona
Early P1
C
(34)
Roflumilast
Lymphoma
University of Arizona
Early P1
C
(34)
SIMVASTATIN
Lymphoma
Masonic Cancer Center, University of Minnesota
Early P1
C
(34)
Showing 201 to 225 of 228 assets
Previous
Page 9 of 10
Next
